<DOC>
	<DOCNO>NCT00828646</DOCNO>
	<brief_summary>The purpose study evaluate safety profile , tolerability , pharmacokinetics , pharmacodynamics follow 14-day multiple oral dos BMS-708163 healthy young male Japanese healthy elderly male female Japanese subject</brief_summary>
	<brief_title>Safety Study Multiple-dose Gamma-secretase Inhibitor Healthy Male Japanese Healthy Elderly Japanese</brief_title>
	<detailed_description />
	<criteria>Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Body Mass Index ( BMI ) 19 25 kg/m2 , inclusive . BMI = weight ( kg ) / [ height ( ) ] 2 Men , age 20 45 , men woman [ childbearing potential ( i.e. , postmenopausal surgically sterile ) ] , age 65 older . Women consider surgically sterile undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy . Women consider postmenopausal amenorrhea ≥12 consecutive month , woman hormone replacement therapy ( HRT ) , document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL WOCBP Women pregnant breastfeed Women positive pregnancy test enrollment prior administration investigational product Sexually active fertile men use effective birth control partner WOCBP Any significant acute chronic medical illness Any current recent ? medical history gastrointestinal disease may affect evaluation study treatment History recent major surgery gastrointestinal surgery may impact evaluation absorption study drug History blood donation blood transfusion within 4 week prior study treatment Intolerance oral medication venous access QTc interval ( Bazett 's correction ) &gt; 500 m screen Smoking 10 cigarette per day Recent ( within 6 month ) drug alcohol abuse define DSM IV Any sound medical , psychiatric and/or social reason determine investigator Subjects ≥ 65 yr allow agerelated minimum mild abnormality vital sign ( i.e . blood pressure ) laboratory test ( i.e . blood sugar , serum cholesterol , serum triglyceride ) far deem sign consequence illness organ dysfunction subject medical treatment Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination Positive urine screen drug abuse Positive blood screen hepatitis C antibody , HIV hepatitis B antigen Indicators abnormal renal function baseline : urine protein History allergy GammaSecretase Inhibitor related compound History significant drug allergy Prior exposure BMS708163 Exposure investigational drug placebo within 4 week study drug administration Use prescription drug overthecounter acid controller within 4 week prior study drug administration Use drug , include overthecounter medication herbal preparation , within 2 week prior study drug administration Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Healthy Subjects</keyword>
</DOC>